डोसेटैक्सेल के इंटरैक्शन

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. (डोसेटैक्सेल लेबल, बॉक्स्ड चेतावनी)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients who have previously experienced a hypersensitivity reaction to paclitaxel may develop a hypersensitivity reaction to docetaxel that may include severe or fatal reactions such as anaphylaxis. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

The alcohol content in a dose of Docetaxel Injection may affect the central nervous system and should be taken into account for patients in whom alcohol intake should be avoided or minimized. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Concomitant use of Docetaxel Injection and drugs that inhibit CYP3A4 may increase exposure to docetaxel and should be avoided. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

In BCIRG006, a total of 2.9% (31/1056) of patients in the TCH (docetaxel, carboplatin, trastuzumab) arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued trastuzumab due to cardiac toxicity. (ट्रैस्टुज़ुमैब लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

In the 251 patients with metastatic breast cancer who received XELODA with docetaxel, 68% had grade 3 or 4 neutropenia, 2.8% had grade 3 or 4 thrombocytopenia, and 10% had grade 3 or 4 anemia. (कैपेसिटाबिन लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

In the adjuvant breast cancer trial (TAX316) AML occurred in 3 of 744 patients who received docetaxel, doxorubicin, and cyclophosphamide (TAC) and in 1 of 736 patients who received fluorouracil, doxorubicin, and cyclophosphamide [ see Clinical Studies (14.2) ]. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Treatment-related AML or MDS has occurred in patients given anthracyclines and/or cyclophosphamide, including use in adjuvant therapy for breast cancer. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

In gastric cancer patients treated with docetaxel in combination with cisplatin and fluorouracil (TCF), febrile neutropenia and/or neutropenic infection occurred in 12% of patients receiving G-CSF compared to 28% who did not. (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (डोसेटैक्सेल लेबल, चेतावनियां और सावधानियां)